Navigation Links
Transcept Pharmaceuticals to Present at the Susquehanna Financial Group's SIGnificant Investment Options in Healthcare Conference
Date:2/19/2008

PT. RICHMOND, Calif., Feb. 19 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference at the W Hotel, 541 Lexington Avenue, in New York City on Tuesday, March 4, 2008 at 8:30 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc. The Ruth Group

Michael Gill Investors / Media

Director of Communications Stephanie Carrington / Jason Rando

(510) 215-3575 (646) 536-7017 / 7025

mgill@transcept.com scarrington@theruthgroup.com

jrando@theru
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
2. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
4. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. NUCRYST Pharmaceuticals announces year-end results
11. Renhuang Pharmaceuticals, Inc. Retains CCG Elite

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...d women almost equally, study finds, , ,...ed clot-dissolving drug Plavix (clopidogrel) works... major clinical trials has found. , "After this...both men and women with this very important drug,"...cular thrombosis at New York University Langone Me...
(Date:11/9/2009)... Networking is everybody,s buzz word today an...fingClub.com enables Recruiters and Staffers creat..., share, communicate and close positions. The site... profiles and network with recruiters. , ...t Job Market forces everyone to network more than ...
(Date:11/9/2009)...etter formation could boost self-esteem, researche...s) -- Autistic children are more likely to have ha...ers, than those without autism, researchers say. ,...13. Half of the study participants had autism spec...in the normal range for perceptual reasoning on an...
(Date:11/9/2009)...th new cells regained sexual function, study says,...-- Researchers were able to restore sexual functio...enile tissue in the lab and implanting it, a new s... ways off, researchers say the technique could one...in men. , "We were able to show the tissue was ...
(Date:11/9/2009)...a, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat D... today that Novartis, a US$41 billion internationa... HTDS, H1N1 Vaccine partner, Zhejiang Tianyuan Bio...artis of Switzerland will begin a five-year, $1 bi...will dramatically increase its investment in its C...
Breaking Medicine News(10 mins):Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4
...eam from the Institute Pasteur has recently shown ...ne system in its host's fat cells. //This formidab...erful antibiotics in these cells, in which it may ...radicate the bacillus entirely from infected indiv...
...awl: There's smoked salmon, smoked ham, smoked bac...curean delight//, but smoked rats? It's true, the ...rtheastern Mizoram with some vendors in this capit...o eat, smoked rats are still in demand in Aizawl's...
... Fresh fruits and vegetables besides providing var...rveys report that 33 percent of all children are o...ma – Birmingham, undertook a study in 2004 to zero...e families to consume healthy diet It was e...
...lip K. Hopke, professor and director of Clarkson's...(CARES) is an internationally respected expert// o...al Protection Agency's (EPA) Science advisory boar...nts and respiratory illnesses. "Epidemiologi...
...aazar, a deadly parasitic disease transmitted by t... people, mostly poor, and claimed 93 lives// so fa...38 districts in its grip. Known as the poor ...Manjhi is desperate to earn more money to treat hi...
...n cells get stressed, their proteins go unfolded. ...nfolded protein response. // Now, new resea...enomenon actually serves a protective role; rather...iseases including Huntington's and Parkinson's are...
Other Medicine News:Health News:Tuberculosis: The Bacillus Takes Refuge in Adipose Cells 2Health News:Smoking Out Rats from Fields to Mizoram’s Dining Table 2Health News:Do Children Of Low Income Families Eat Fresh Fruits?, 2Health News:Research on to Find Link Between Airborne Pollutants and Respiratory Illness 2Health News:Kalaazar sweeping through Bihar, 93 dead 2Health News:Unfolded Proteins May Protect Cells from Dying 2
(Date:11/9/2009)..., Mass., Nov. 9 Boston S...d the launch of its COGNIS® cardiac resynchro...® implantable cardioverter defibrillator (ICD...panese Ministry of Health, Labor and Welfare (MHLW... September. COGNIS and TELIGEN are the result of ...
(Date:11/9/2009)...IA BEACH, Va., Nov. 9 LifeNet Heal...nces the launch of Vertigraft Cervical Bio-Implant...ervon® is a new, proprietary glycerol-based p...lants to be stored in a fully hydrated state at am...eze or freeze-dry bio-implants, doing away with le...
(Date:11/9/2009)...TON JUNCTION, N.J., Nov. 9 Unwaver...al devices, but recognizing today,s economic clima...ality aesthetic laser systems, introduces the MOSA...ed at under $50,000. ,, The MOSAIC CO2 offers ...al technology including scanning and stamping oper...
Breaking Medicine Technology:Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4LifeNet Health Announces First Bio-Implant with New Preservation Technology 2Lutronic(R) Unleashes the New MOSAIC CO2 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 1Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 2Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 3Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 4Virtify Inc Delivers Industrys First Enterprise Content Compliance Software Suite for Life Sciences Companies 12722 5Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 1Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 2Unique Facility Designed for the Comfort of Hospice Patients and Their Families 49585 3
...Two Noted Cardiothoracic Surgeons to Lead Pivotal ...t Inc. today announced that it has appointed David...ncipal Investigator for its Bridge-to-Transplant t... generation DuraHeart(TM) Left Ventricular Assist ...ni, Director of the Heart Transplant and Center fo...
...erence Call Today at 5:00 p.m. Eastern Time - , ...harmaceuticals, Inc. (Nasdaq: PARD ), a biopharm...ted financial results for the fourth quarter and y...ate update. , , "During the fourth quarter of 20...f developing picoplatin as an oncology platform co...
Other Medicine Technology:David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9
...fits all plug. Once inserted into the punctum, For...ates, Form Fit increases in size until it complete... perfect fit. ,The Form Fit plug is made of a h..., gelatinous material when it contacts tear film. ...
Total Intact PTH IRMA
Nichols Advantage Quick-IntraOperative Bio-Intact PTH (1-84)
...exclusively distributed by Medtronic, sets the sta...erative imaging with surgical navigation in a comp...ne of the most comprehensive neurosurgical tools a...from a low-field magnet , Superior capabilities ...
Medicine Products: